| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
38,180,000 |
| Market
Cap: |
56.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.48 - $1.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile TCR2 Therapeutics is a clinical-stage cell therapy company developing T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its TCR Fusion Construct T cells (TRuC-T cells). Co.'s TRuC-T cells recognize and kill cancer cells by using the entire TCR signaling complex. Co.'s TRuC-T cell targeting mesothelin-expressing solid tumors are: gavocabtagene autoleucel, in which Co. is conducting its clinical trial to treat patients with non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma or cholangiocarcinoma; and TC-510, which incorporates a PD-1:CD28 chimeric switch receptor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
121,863 |
468,513 |
| Total Buy Value |
$0 |
$0 |
$226,133 |
$885,368 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
5 |
9 |
| Total Shares Sold |
0 |
0 |
140,340 |
287,401 |
| Total Sell Value |
$0 |
$0 |
$263,840 |
$445,404 |
| Total People Sold |
0 |
0 |
2 |
6 |
| Total Sell Transactions |
0 |
0 |
2 |
33 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Menzel Garry E |
President and CEO |
• • – |
2022-12-13 |
4 |
AS |
$1.06 |
$11,682 |
D/D |
(11,000) |
138,871 |
|
77% |
|
| Olagunju Peter |
Chief Technical Officer |
• – – |
2022-12-12 |
4 |
AS |
$1.10 |
$1,766 |
D/D |
(1,610) |
25,751 |
|
64% |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2022-12-12 |
4 |
AS |
$1.10 |
$5,040 |
D/D |
(4,586) |
114,211 |
|
64% |
|
| Menzel Garry E |
President and CEO |
• • – |
2022-12-12 |
4 |
AS |
$1.10 |
$11,674 |
D/D |
(10,613) |
149,871 |
|
64% |
|
| Justice Angela |
Chief People Officer |
• – – |
2022-12-12 |
4 |
AS |
$1.06 |
$6,298 |
D/D |
(5,828) |
48,745 |
|
64% |
|
| Olagunju Peter |
Chief Technical Officer |
• – – |
2022-12-09 |
4 |
AS |
$1.13 |
$1,765 |
D/D |
(1,561) |
27,361 |
|
52% |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2022-12-09 |
4 |
AS |
$1.13 |
$5,041 |
D/D |
(4,461) |
118,797 |
|
52% |
|
| Menzel Garry E |
President and CEO |
• • – |
2022-12-09 |
4 |
AS |
$1.13 |
$11,678 |
D/D |
(10,325) |
160,484 |
|
52% |
|
| Justice Angela |
Chief People Officer |
• – – |
2022-12-09 |
4 |
AS |
$1.13 |
$3,149 |
D/D |
(2,792) |
54,573 |
|
52% |
|
| Olagunju Peter |
Chief Technical Officer |
• – – |
2022-12-08 |
4 |
AS |
$1.25 |
$1,767 |
D/D |
(1,410) |
28,922 |
|
43% |
|
| Menzel Garry E |
President and CEO |
• • – |
2022-12-08 |
4 |
AS |
$1.25 |
$11,680 |
D/D |
(9,314) |
170,809 |
|
43% |
|
| Justice Angela |
Chief People Officer |
• – – |
2022-12-08 |
4 |
AS |
$1.26 |
$3,151 |
D/D |
(2,511) |
57,365 |
|
43% |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2022-12-08 |
4 |
AS |
$1.26 |
$5,042 |
D/D |
(4,014) |
123,258 |
|
43% |
|
| Olagunju Peter |
Chief Technical Officer |
• – – |
2022-12-07 |
4 |
AS |
$1.28 |
$1,767 |
D/D |
(1,378) |
30,332 |
|
37% |
|
| Menzel Garry E |
President and CEO |
• • – |
2022-12-07 |
4 |
AS |
$1.28 |
$11,680 |
D/D |
(9,111) |
180,123 |
|
37% |
|
| Justice Angela |
Chief People Officer |
• – – |
2022-12-07 |
4 |
AS |
$1.28 |
$3,150 |
D/D |
(2,457) |
59,876 |
|
37% |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2022-12-07 |
4 |
AS |
$1.28 |
$5,040 |
D/D |
(3,928) |
127,272 |
|
37% |
|
| Menzel Garry E |
President and CEO |
• • – |
2022-12-06 |
4 |
AS |
$1.35 |
$20,081 |
D/D |
(14,886) |
189,234 |
|
23% |
|
| Justice Angela |
Chief People Officer |
• – – |
2022-12-06 |
4 |
AS |
$1.33 |
$3,150 |
D/D |
(2,361) |
62,333 |
|
23% |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2022-12-06 |
4 |
AS |
$1.33 |
$5,040 |
D/D |
(3,778) |
131,200 |
|
23% |
|
| Olagunju Peter |
Chief Technical Officer |
• – – |
2022-12-06 |
4 |
AS |
$1.33 |
$1,765 |
D/D |
(1,327) |
31,710 |
|
23% |
|
| Menzel Garry E |
President and CEO |
• • – |
2022-12-05 |
4 |
AS |
$1.37 |
$11,703 |
D/D |
(8,530) |
204,120 |
|
20% |
|
| Justice Angela |
Chief People Officer |
• – – |
2022-12-05 |
4 |
AS |
$1.37 |
$3,161 |
D/D |
(2,302) |
64,694 |
|
20% |
|
| Cardama Alfonso Quintas |
Chief Medical Officer |
• – – |
2022-12-05 |
4 |
AS |
$1.37 |
$5,050 |
D/D |
(3,686) |
134,978 |
|
20% |
|
| Olagunju Peter |
Chief Technical Officer |
• – – |
2022-12-05 |
4 |
AS |
$1.37 |
$1,766 |
D/D |
(1,291) |
33,037 |
|
20% |
|
132 Records found
|
|
Page 2 of 6 |
|
|
